August 13, 2014 12:19 PM

Durham's BioCryst awarded $4.1 million to research Ebola treatment

BioCryst Pharmaceuticals, a small drug developer in Durham, raised its profile in the fight against Ebola on Wednesday by announcing it was awarded $4.1 million in federal research funds to develop a potential treatment for the deadly virus.

Related content

Suggested for you



Editor's Choice Videos